J&J plans to submit 10 new drugs for approval by 2017

Johnson & Johnson's pharmaceuticals segment plans to submit 10 new product filings for regulatory approval over the next four years. These products are aimed at addressing serious unmet medical needs, such as Hepatitis C, schizophrenia and influenza.

"Our investment in transformational innovation has enabled strong growth that has allowed us to continue investing in our future portfolio. With a steadfast focus on the most serious unmet medical needs, our approach is to identify the best science — internal and external — to deliver new options and solutions to patients. Today, we have an industry-leading pipeline of truly differentiated products and a track record of success resulting in more new molecular entity (NME) approvals per year at a lower development cost than the industry average."

Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson, and Worldwide Chairman, Pharmaceuticals Group.

J&J also plans to continue accelerating its development stage pipeline in both Japan and China. Three NMEs and three brand line extensions are currently in registration in Japan, and J&J plans to file two additional NMEs and six brand line extensions by 2017. In China, four NMEs and four line extensions are currently in registration, and J&J plans to file nine NMEs and six brand line extensions by 2017.

"We've spent the past five years transforming our business, and the growth we're seeing today is the direct impact of that effort. The innovative new therapies in our pipeline will drive our next wave of growth. With strong momentum across our global Pharmaceuticals segment, we are executing well against our commercial strategy to gain market share and ensure greater access to our medicines. We're also strengthening our presence in critical geographies and have nearly doubled our footprint in emerging markets during the last five years."

Joaquin Duato, Worldwide Chairman, Pharmaceuticals Group.

According to IMS Health, the total global pharma market is expected to grow approximately 4.5% annually and reach a market size of around US $1.2 trillion by 2017. J&J's pharmaceuticals segment was the fastest growing pharma business in the US, Europe and Japan in 2012.